SGLT2 inhibitors are a new family of agents, which occlude the path of SGLT2 glucose reabsorption and cause glucosuria. Efficacy of SGLT2 inhibitors includes reduction of HbA1c, fasting and ...

Medically reviewed by Mary Choy, PharmD Farxiga (dapagliflozin) is an orally administered, brand-name medication classified ...

SGLT2 inhibitors for type 2 diabetes work by eliminating excess glucose in the urine. It not only brings the blood sugar down but also aids with weight reduction.

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

SGLT-2 inhibitors vs DPP-4 inhibitors were associated with a reduced risk for liver cirrhosis among patients with type 2 diabetes.

They added that “it seems very likely that SGLT2 inhibitors will also result in a substantial reduction in recurrent stone events in patients with pure [calcium oxalate] stones.” Despite the concern ...

The researchers found that both SGLT2 inhibitors and GLP-1 agonists were associated with a lower risk of major cardiovascular events, but the drug effects varied with the patients’ age.

BOSTON -- Sodium-glucose cotransporter-2 (SGLT2) inhibitors were linked to long ... "I think we cannot make any major ...

SGLT2 inhibitors also lowered AKI risk, but “more work needs to be done to optimize their utilization, especially in high-risk populations in Asia and beyond.” ...

Opens in a new tab or window Comparative effectiveness study followed adults with type 2 diabetes who initiated SGLT-2 inhibitors from 2014 to 2020. Real-world outcomes largely point to comparable ...

Adults with overweight or obesity and type 2 diabetes who are given the sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin ... for the submitted work; no financial relationships ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of cardiovascular disease.